Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment (TROPIC) (2010)

Peer-Reviewed Study · de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ, Shen L, Roessner M, Gupta S, Sartor AO; TROPIC Investigators · October 2, 2010

de Bono JS et al., 2010-10-02: TROPIC randomised 755 men whose disease progressed during or after docetaxel to cabazitaxel or mitoxantrone, both with prednisone. Cabazitaxel extended median survival by 2.4 months (15.1 vs 12.7; HR 0.70) at the cost of much more grade 3+ neutropenia (82% vs 58%) and 8% febrile neutropenia.

median survival was 15·1 months (95% CI 14·1-16·3) in the cabazitaxel group and 12·7 months (11·6-13·7) in the mitoxantrone group. The hazard ratio for death of men treated with cabazitaxel compared with those taking mitoxantrone was 0·70

Abstract (FINDINGS)

de Bono JS et al., 2010-10-02: TROPIC randomised 755 men whose disease progressed during or after docetaxel to cabazitaxel or mitoxantrone, both with prednisone. Cabazitaxel extended median survival by 2.4 months (15.1 vs 12.7; HR 0.70) at the cost of much more grade 3+ neutropenia (82% vs 58%) and 8% febrile neutropenia. Funder: 'FUNDING: Sanofi-Aventis.' Design/analysis: 'JSB and AOS designed the trial protocol and analysed the data, with input from the sponsor, who funded the trial… The sponsor funded editorial assistance and reviewed the final draft'. Maker: Sanofi (Jevtana). Comparator: mitoxantrone plus prednisone. A contract research organisation handled randomisation with no other involvement. Study type: randomized trial.